Venture Partners

  • Sir Andrew Witty

    Venture Partner

    Sir Andrew Witty

    Andrew is Chancellor of the University of Nottingham and recently retired as Chief Executive Officer of GlaxoSmithKline plc, a position he held between 2008 and 2017.

    Andrew joined Glaxo in 1985 and held a variety of roles in the UK and overseas, including South Africa, the USA and Singapore. During his tenure GSK consistently achieved the Top Position in every Access to Medicine Index.

    While in Singapore Andrew was also a Board Member of the Singapore Economic Development Board and the Singapore Land Authority. In 2003 he was awarded the Public Service Star.

    Andrew has served in numerous advisory roles to governments around the world including South Africa, Guangzhou China and the UK, where he was a member of the Prime Minister’s Business Advisory Group from 2010-2015. In 2012 Andrew was awarded a knighthood for services to the economy and the UK pharmaceutical industry. In 2014, he was appointed as a Business Ambassador for the UK Government and in 2015 Andrew became a Member of the Advisory Council for the China-Britain Business Council.

    Andrew was President of the European Federation of Pharmaceutical Industries and Associations from 2010 to 2013. From 2013 to 2015 he was the only pharmaceutical industry representative in the UNAIDS-Lancet Commission for Defeating AIDS and Advancing Global Health. In November 2015 Andrew was appointed as a Member of the UN High-Level Panel on Access to Medicines. In May 2016, Andrew became a Visiting Professor at the Institute of Global Health Innovation at Imperial College, London. He is a Non Executive Director of United Healthcare and G1 Therapeutics and Council Member of the London School of Health and Tropical Medicine.

    Andrew has a Joint Honours BA in Economics from the University of Nottingham and holds Honorary Degrees from the Universities of Exeter, Manchester and Nottingham.

  • Fred Goldwater

    Venture Partner

    Fred Goldwater

    Fred Goldwater provides strategic advisory services and executive support to companies serving the healthcare market. He has more than 35 years of executive management experience in manufacturing, financial services, healthcare and an extensive background in business development (including mergers, acquisitions, joint ventures and large-scale project development/implementations), operations, information systems, marketing and product development. He currently is COO of Aligncare Services, a provider of care analytics. Recently, he was COO of Community Care of North Carolina Services Inc., the for-profit subsidiary of CCNC, a Medicaid population health management company. He served as CEO of RealMed, a revenue cycle management company providing services to providers and payers and managed its sale to Availity. Recent consulting assignments include BCBSNC, Cain Brothers, CivaTech, Clinverse, FastMed, LipoScience, Medikidz, NC HIE and Technosoft.

    At the end of 2007, Fred retired from Blue Cross and Blue Shield of North Carolina. He had various responsibilities during his tenure including SVP of Strategic Development and CIO, SVP of Operations which included segment responsibilities for self-insured, government and senior markets. Prior to Blue Cross and Blue Shield, he was employed with Providian (formerly Capital Holding Corporation) and WestRock. Fred earned an MBA from Pace University in New York and an undergraduate degree from Babson College in Massachusetts.

    Community and Board Engagements:

    Fred currently serves as a board observer and strategic advisor to i2i Population Health and is on the Board of the Chamber Orchestra of the Triangle.

  • Holden Thorp

    Venture Partner

    Holden Thorp

    Holden Thorp is Provost and Executive Vice Chancellor for Academic Affairs at Washington University in St. Louis where he is also Rita Levi-Montalcini Distinguished University Professor and holds appointments in both chemistry and medicine.

    Thorp joined WashU after spending three decades at the University of North Carolina at Chapel Hill where he served as the 10th chancellor from 2008 through 2013.

    Thorp started at UNC as an undergraduate student and earned a bachelor of science degree in chemistry with highest honors in 1986. He earned a doctorate in chemistry in 1989 at the California Institute of Technology and completed post-doctoral work at Yale University.

    In his research career, Thorp developed technology for electronic DNA chips and co-founded Viamet Pharmaceuticals, which is commercializing new drugs for fungal disease and developed the prostate cancer assets that are now being commercialized by Innocrin Pharmaceuticals.

    Community and Board Engagements:

    Thorp is currently a member of the National Security Higher Education Advisory Board, the Board of Trustees of the National Humanities Center, the Board of Trustees of the St. Louis Symphony Orchestra, and the Board of Directors of Barnes-Jewish Hospital.

  • Myla Lai-Goldman, MD

    Venture Partner

    Myla Lai-Goldman, MD

    Dr. Myla Lai-Goldman has over 25 years’ experience in the development, commercialization and adoption of novel molecular diagnostic assays. In 2011, with Drs. Chuck Perou and Neil Hayes of the University of North Carolina at Chapel Hill, she co-founded GeneCentric Therapeutics, a Hatteras Fund III company, whose Cancer Subtype Platform (CSP™) provides an advanced molecular cancer classification for augmented drug response. GeneCentric’s lead product is the Lung Subtype Platform (LSP™).

    Until her retirement on December 31, 2008, Myla was Executive Vice President, Chief Medical Officer of Laboratory Corporation of America® Holdings (LabCorp®), where she managed LabCorp’s National Office of Quality and Science, through which she was responsible for all quality, science and medical activities for LabCorp and its subsidiaries. From 1998 until April 2008, Myla also served as Chief Scientific Officer of the company, where she was responsible for R & D. Until 2006, she managed the operations of the Company’s Center for Molecular Biology and Pathology in Research Triangle Park, NC; National Genetics Institute, Inc. in Los Angeles, CA; and ViroMed Laboratories, Inc. in Minneapolis, MN. Additionally, she held the position of Medical Director for the Center for Molecular Biology and Pathology from 1991 to 2005. Myla joined the Company in 1990.

    Myla earned an MD from the College of Physicians and Surgeons at Columbia University in New York, and completed postgraduate training in Internal Medicine at St Luke’s Hospital in New York, anatomic and clinical pathology at the UCLA Center for Health Sciences, and hematopathology at the University of North Carolina at Chapel Hill. She is board-certified in anatomic and clinical pathology.

    Community and Board Engagements:

    Myla serves as a board member for West Pharmaceutical Services and Qvella Corporation.

  • Robert Morff, PhD

    Venture Partner

    Robert Morff, PhD

    Bob has deep experience in medical devices and diagnostics product and business development. He was interim CEO and a director at Pathfinder Technologies, and currently serves as a director at HistoSonics. He was VP and CSO of the Wallace Coulter Foundation, CEO of Ondine Biopharma, Principal at Senmed Medical Ventures, and Senior Research Scientist in Eli Lilly’s Medical Devices and Diagnostics Division. He has founded and led several companies in the microfluidics, stem cell, and tissue engineering areas.

    When Bob was with Eli Lilly’s Medical Devices and Diagnostics Division, he led the research teams that developed the first commercially available continuous glucose monitor and the first closed-loop drug delivery pump.

    Bob graduated from the University of Missouri with a B.S. and M.S. in electrical engineering, and a Ph.D. in medical physiology.

    Community and Board Engagements:

    Bob remains engaged with the Coulter Foundation, where he serves as a lecturer, mentor and business advisor for their NIH/Coulter C3i Program. He is an advisor/mentor for the Kauffman Foundation’s PIPELINE entrepreneurs program, and serves on review and advisory committees for a number of universities, including the University of Missouri, Duke University, Clemson University, and MUSC.